Developer docs
API playgroundTry for free, no card

Search company profiles

Asclepii

Full company profile

uuid0002adi

Namestring
Asclepii
Legal namestring
Asclepii
Websiteurl
asclepii.com
Company typeenum
Private
Founded yearint
2022
Short descriptiontext

Asclepii is a Cleveland-based medical device company that develops and sells FDA-cleared nanosilver hydrogel wound dressings (Poseidon) and is building a regenerative extracellular matrix platform (Artemis) for chronic and complex wounds.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wound care dressings, regenerative medicine, nanosilver hydrogel, chronic wound treatment, medical devices
Industry4 codes
PRIMARYHLAHALAC
Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Wound Care Medical Devices
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Poseidon™ Product Sales
TypeHardware Sales
Description

Direct sales of FDA-cleared nanosilver hydrogel wound dressings to consumers, clinics, and distributors. Products sold in 1 oz and 3 oz sizes, as individual units or cases of 12 units. Available in both OTC and Rx formulations.

asclepii.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details4 tiers
1Poseidon™ Nanosilver Hydrogel 1 oz - Individual unit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$260.00 USD per 1 oz unit (consumer OTC pricing). Also available as case of 12 units.

asclepii.com
2Poseidon™ Nanosilver Hydrogel 3 oz - Individual unit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$713.00 USD per 3 oz unit (consumer OTC pricing).

asclepii.com
3Case pricing - 12 units
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$20/oz. Sold in cases of 12 units. Professional/distributor pricing for clinics and resellers.

asclepii.com
4Payment plan option
ModelOtherBilling cadencePay-as-you-go
Notes

Pay in 4 interest-free installments available (e.g., $133.12 x 4 for 1 oz unit).

asclepii.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Poseidon™
Description

FDA-cleared nanosilver hydrogel wound dressing designed to support moisture balance and topical wound management

asclepii.com
+1 more record
Core offering1 text field

Asclepii manufactures and sells the FDA-cleared Poseidon™ Nanosilver Hydrogel wound dressing in 1 oz and 3 oz formats, available OTC to consumers and by prescription to healthcare providers, using an ultra-low 10 ppm silver nanoparticle hydrogel that kills microbes and disrupts biofilms without contributing to antibiotic resistance. The company is also developing the Artemis Regenerative Wound Care Platform, an extracellular matrix scaffold technology for tissue regeneration in chronic and complex wounds such as diabetic foot ulcers and burns, which is being scaled through a manufacturing and commercialization partnership with Nottingham Spirk.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 96% infection-free rate after 8 days - over 20% better than market leader (n=100)
+2 more records
Product overview1 text field

Asclepii offers a portfolio of wound care products centered around the Poseidon™ line of FDA-cleared nanosilver hydrogel wound dressings, available in 1 oz, 3 oz, and tube formats for both prescription (Rx) and over-the-counter (OTC) use. The Poseidon products feature ultra-low silver concentration (1 ppm) nanotechnology that kills microbes and disrupts biofilms without contributing to antibiotic resistance. In parallel, the company is developing the Artemis regenerative wound care platform—an extracellular matrix technology for tissue regeneration targeting chronic and complex wounds. The Poseidon line represents the company's current commercial products while Artemis represents its next-generation regenerative technology in development.

Product and service3 records
1Poseidon™ Nanosilver Hydrogel 1 oz
CategoryWound Care Medical Device
Description

FDA-cleared nanosilver hydrogel wound dressing designed to support moisture balance and topical wound management for consumers (OTC) and healthcare providers (Rx). Uses 10 ppm ultra-low silver nanoparticles to kill harmful microbes and disrupt biofilms without contributing to antibiotic resistance. Clinical observational data showed 96% of patients infection-free after 8 days.

2Poseidon™ Nanosilver Hydrogel 3 oz
CategoryWound Care Medical Device
Description

Larger 3 oz format of the FDA-cleared Poseidon Nanosilver Hydrogel wound dressing with the same ultra-low 10 ppm silver nanoparticle technology for topical wound management. Provides extended coverage for larger wounds and is sold OTC to consumers and by Rx to healthcare providers.

3Artemis Regenerative Wound Care Platform
CategoryRegenerative Medicine Platform
Description

Extracellular matrix technology platform designed to support tissue regeneration and improve healing across chronic and complex wounds including diabetic foot ulcers and burns. Uses semi-synthetic cellular scaffolds that optimize cell adhesion, growth, and vascularization while reducing production costs by eliminating expensive bioreactor-based tissue engineering steps. Being scaled through a manufacturing and commercialization partnership with Nottingham Spirk.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-06
Description

Manufacturing and commercialization partnership to accelerate large-scale manufacturing and nationwide deployment of the Artemis regenerative wound care platform. Collaboration reflects shared commitment to strengthening U.S. biomanufacturing capabilities and addressing chronic wounds affecting approximately 6 million Americans annually. Nottingham Spirk brings expertise in product development and commercialization at scale.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global medical device leader with a large Advanced Wound Management portfolio (hydrogels, silver dressings, bioactives). Directly comparable to Asclepii in silver/antimicrobial wound dressings and adjacent regenerative products, but at vastly greater scale and with deep formulary penetration.

TypeBroad incumbent
Description

Specialist in advanced wound care, ostomy, and continence products, with a portfolio that includes silver-containing AQUACEL Ag dressings. Directly competes in the antimicrobial advanced wound dressing category Asclepii targets.

TypeBroad incumbent
Description

Major wound care and ostomy player with Biatain Ag and similar silver-based dressings. Targets the same chronic wound (diabetic foot ulcer, pressure ulcer) end-markets and clinician segments as Asclepii.

TypeBroad incumbent
Description

Swedish advanced wound care company (Mepilex Ag, Mepitel) and a global leader in antimicrobial and foam dressings. A direct head-to-head incumbent in the antimicrobial wound dressing category.

TypeBroad incumbent
Description

Owns the legacy KCI/Acelity negative pressure wound therapy franchise plus advanced wound dressings. Comparable to Asclepii as a broad incumbent in hospital-channel chronic wound care, though with a different primary modality.

TypeDirect peer
Description

Commercializes Apligraf and Dermagraft, the leading FDA-approved skin substitute / regenerative wound care products. Closest direct analog to Asclepii's Artemis platform, although priced at a premium tier.

TypeDirect peer
Description

Develops regenerative tissue technologies (Integra Dermal Regeneration Template) and a broad wound care portfolio. Directly comparable to Asclepii's regenerative wound care ambition through Artemis.

TypeDirect peer
Description

Sells dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for chronic wound healing. Comparable regenerative approach and end-market overlap with Asclepii's Artemis platform.

TypeEmerging player
Description

Israeli-listed biotech commercializing NexoBrid for burn wound debridement and developing a bioengineered skin substitute. Comparable to Asclepii in targeting chronic and burn wounds with a regenerative/biologic modality.

TypeEmerging player
Description

Regenerative medicine company developing autologous skin and soft tissue products (SkinTE). Comparable to Asclepii's Artemis as a smaller, emerging regenerative wound care player with similar early-stage commercialization challenges.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Asclepii

Wound Care Medical Devicesasclepii.com

Asclepii is a Cleveland-based medical device company that develops and sells FDA-cleared nanosilver hydrogel wound dressings (Poseidon) and is building a regenerative extracellular matrix platform (Artemis) for chronic and complex wounds.

Asclepii firmographics

Firmographics
Name
Asclepii
Legal name
Asclepii
Website
https://asclepii.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Asclepii is a Cleveland-based medical device company that develops and sells FDA-cleared nanosilver hydrogel wound dressings (Poseidon) and is building a regenerative extracellular matrix platform (Artemis) for chronic and complex wounds.
Ownership category
akta.pro rank

Asclepii industry classification

Industry
Product category
Wound Care Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHALAC
Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Wound care dressings
  • Regenerative medicine
  • Nanosilver hydrogel
  • Chronic wound treatment
  • Medical devices

Where Asclepii is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Asclepii business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Poseidon™ Product Sales: Direct sales of FDA-cleared nanosilver hydrogel wound dressings to consumers, clinics, and distributors. Products sold in 1 oz and 3 oz sizes, as individual units or cases of 12 units. Available in both OTC and Rx formulations.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goPoseidon™ Nanosilver Hydrogel 1 oz - Individual unit
Unit PricingPay-as-you-goPoseidon™ Nanosilver Hydrogel 3 oz - Individual unit
Unit PricingPay-as-you-goCase pricing - 12 units
OtherPay-as-you-goPayment plan option

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Asclepii product offering

Product offering

Core offering

Asclepii manufactures and sells the FDA-cleared Poseidon™ Nanosilver Hydrogel wound dressing in 1 oz and 3 oz formats, available OTC to consumers and by prescription to healthcare providers, using an ultra-low 10 ppm silver nanoparticle hydrogel that kills microbes and disrupts biofilms without contributing to antibiotic resistance. The company is also developing the Artemis Regenerative Wound Care Platform, an extracellular matrix scaffold technology for tissue regeneration in chronic and complex wounds such as diabetic foot ulcers and burns, which is being scaled through a manufacturing and commercialization partnership with Nottingham Spirk.

Product overview

Asclepii offers a portfolio of wound care products centered around the Poseidon™ line of FDA-cleared nanosilver hydrogel wound dressings, available in 1 oz, 3 oz, and tube formats for both prescription (Rx) and over-the-counter (OTC) use. The Poseidon products feature ultra-low silver concentration (1 ppm) nanotechnology that kills microbes and disrupts biofilms without contributing to antibiotic resistance. In parallel, the company is developing the Artemis regenerative wound care platform—an extracellular matrix technology for tissue regeneration targeting chronic and complex wounds. The Poseidon line represents the company's current commercial products while Artemis represents its next-generation regenerative technology in development.

Differentiator

Problem solved

Functional benefit

Brands

  • Poseidon™: FDA-cleared nanosilver hydrogel wound dressing designed to support moisture balance and topical wound management
  • Artemis

Products and services

  • Poseidon™ Nanosilver Hydrogel 1 oz FDA-cleared nanosilver hydrogel wound dressing designed to support moisture balance and topical wound management for consumers (OTC) and healthcare providers (Rx). Uses 10 ppm ultra-low silver nanoparticles to kill harmful microbes and disrupt biofilms without contributing to antibiotic resistance. Clinical observational data showed 96% of patients infection-free after 8 days.
  • Poseidon™ Nanosilver Hydrogel 3 oz Larger 3 oz format of the FDA-cleared Poseidon Nanosilver Hydrogel wound dressing with the same ultra-low 10 ppm silver nanoparticle technology for topical wound management. Provides extended coverage for larger wounds and is sold OTC to consumers and by Rx to healthcare providers.
  • Artemis Regenerative Wound Care Platform Extracellular matrix technology platform designed to support tissue regeneration and improve healing across chronic and complex wounds including diabetic foot ulcers and burns. Uses semi-synthetic cellular scaffolds that optimize cell adhesion, growth, and vascularization while reducing production costs by eliminating expensive bioreactor-based tissue engineering steps. Being scaled through a manufacturing and commercialization partnership with Nottingham Spirk.

Quantifiable outcome

  • 96% infection-free rate after 8 days - over 20% better than market leader (n=100)
  • +2 more outcomes

Companies that use Asclepii

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Asclepii technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Asclepii partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Nottingham SpirkflagshipStrategic or Co-development Partner · 6 May 2026Manufacturing and commercialization partnership to accelerate large-scale manufacturing and nationwide deployment of the Artemis regenerative wound care platform. Collaboration reflects shared commitment to strengthening U.S. biomanufacturing capabilities and addressing chronic wounds affecting approximately 6 million Americans annually. Nottingham Spirk brings expertise in product development and commercialization at scale.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Asclepii competitors and assessment

Company assessment

Broad incumbents

  • Smith & Nephew: Global medical device leader with a large Advanced Wound Management portfolio (hydrogels, silver dressings, bioactives). Directly comparable to Asclepii in silver/antimicrobial wound dressings and adjacent regenerative products, but at vastly greater scale and with deep formulary penetration.
  • ConvaTec: Specialist in advanced wound care, ostomy, and continence products, with a portfolio that includes silver-containing AQUACEL Ag dressings. Directly competes in the antimicrobial advanced wound dressing category Asclepii targets.
  • Coloplast: Major wound care and ostomy player with Biatain Ag and similar silver-based dressings. Targets the same chronic wound (diabetic foot ulcer, pressure ulcer) end-markets and clinician segments as Asclepii.
  • Mölnlycke Health Care: Swedish advanced wound care company (Mepilex Ag, Mepitel) and a global leader in antimicrobial and foam dressings. A direct head-to-head incumbent in the antimicrobial wound dressing category.
  • 3M Health Care (Solventum): Owns the legacy KCI/Acelity negative pressure wound therapy franchise plus advanced wound dressings. Comparable to Asclepii as a broad incumbent in hospital-channel chronic wound care, though with a different primary modality.

Direct peers

  • Organogenesis: Commercializes Apligraf and Dermagraft, the leading FDA-approved skin substitute / regenerative wound care products. Closest direct analog to Asclepii's Artemis platform, although priced at a premium tier.
  • Integra LifeSciences: Develops regenerative tissue technologies (Integra Dermal Regeneration Template) and a broad wound care portfolio. Directly comparable to Asclepii's regenerative wound care ambition through Artemis.
  • MiMedx: Sells dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for chronic wound healing. Comparable regenerative approach and end-market overlap with Asclepii's Artemis platform.

Emerging players

  • MediWound: Israeli-listed biotech commercializing NexoBrid for burn wound debridement and developing a bioengineered skin substitute. Comparable to Asclepii in targeting chronic and burn wounds with a regenerative/biologic modality.
  • PolarityTE: Regenerative medicine company developing autologous skin and soft tissue products (SkinTE). Comparable to Asclepii's Artemis as a smaller, emerging regenerative wound care player with similar early-stage commercialization challenges.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Asclepii social profiles

Digital presence

Asclepii compliance and trust

Trust signal

Compliance2 records

Asclepii financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Asclepii leadership team

Management profile

Number of profiles

Profiles1 record

Asclepii funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Asclepii M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asclepii

What does Asclepii do?

Asclepii manufactures and sells the FDA-cleared Poseidon™ Nanosilver Hydrogel wound dressing in 1 oz and 3 oz formats, available OTC to consumers and by prescription to healthcare providers, using an ultra-low 10 ppm silver nanoparticle hydrogel that kills microbes and disrupts biofilms without contributing to antibiotic resistance. The company is also developing the Artemis Regenerative Wound Care Platform, an extracellular matrix scaffold technology for tissue regeneration in chronic and complex wounds such as diabetic foot ulcers and burns, which is being scaled through a manufacturing and commercialization partnership with Nottingham Spirk.

Is Asclepii a public or private company?

Asclepii is a private company. It is classified as venture growth investor backed and is currently operating.

When was Asclepii founded?

Asclepii was founded in 2022. It employs 11 to 50 people.

Where is Asclepii based?

Asclepii is headquartered in Cleveland, United States, in the North America region.

How does Asclepii make money?

One revenue line is on record: poseidon™ Product Sales.

Who are Asclepii's main competitors?

Broad incumbents on record are Smith & Nephew, ConvaTec, Coloplast, Mölnlycke Health Care and 3M Health Care (Solventum). Direct peers are Organogenesis, Integra LifeSciences and MiMedx. Emerging players are MediWound and PolarityTE.

Does Asclepii have an API?

No public API is recorded for Asclepii.

What industry is Asclepii in?

Asclepii's product category is Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAC, Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation), with a secondary code of HLAHALAA, Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals